UK Industry Pleased With Brexit Committee's Focus On Regulation
Industry group ABPI is focusing on the fact that the report from parliamentarians on the cross-party Exiting the EU Committee has made at least some mention of the need to ensure that medicines regulation is ready for Brexit on “day one.”
You may also be interested in...
UK based QPPVs are worried about the direct and tangible impact of Brexit on their current jobs, fearing that the QPPV role may either completely vanish from the UK or have its authority undermined.
Professor Sir Michael Rawlins, chair of the MHRA, has told a UK committee of his concerns over Brexit, including possible delays in access to new drugs, a decline in revenues for regulatory work on behalf of the EU, and the possibility that some firms’ HQs might follow the European Medicines Agency if it relocates to another European country.
The European Medicines Agency is working to ensure it can cope with the many challenges it will face as a result of the UK leaving the EU. Those challenges could include the agency losing 50% of its staff, according to the EMA’s deputy head Noel Wathion.